NERVGEN PHARMA CORP.
NGEN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NGEN
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic conditions, with a lead program (NVG-291) that has completed a Phase 1b/2a study and is preparing for a Phase 3 registrational trial.
Key risk: Clinical and regulatory risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 1 clinical trial for NERVGEN PHARMA CORP..
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic conditions, with a lead program (NVG-291) that has completed a Phase 1b/2a study and is preparing for a Phase 3 registrational trial.
- NervGen is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions [news · 2026-04-07].
- The company completed an End-of-Phase 2 meeting with the FDA and restored a Phase 3 registrational trial for NVG-291 to treat chronic tetraplegia [news · 2026-04-07].
- As of 2025-12-31, NervGen reported cash & equivalents of $22.1M, net income of -$44.1M, and shareholders' equity of -$2.0M [sec].
- In May 2026, NervGen announced and priced a $60.0 million public offering of securities [news · 2026-05-21][news · 2026-05-22].
- The company appointed Keith Vendola as Chief Financial Officer in April 2026 [news · 2026-04-27] and Dr. Adam Rogers as CEO in February 2026 [sec · filed 2026-02-10].
What works
- NVG-291 has shown durable improvement in function, independence, and quality of life in chronic spinal cord injury in the Phase 1b/2a CONNECT SCI Study [news · 2026-02-11].
- The company has secured FDA alignment through an End-of-Phase 2 meeting, enabling a Phase 3 registrational trial for chronic tetraplegia [news · 2026-04-07].
- NervGen raised $60.0 million in a public offering in May 2026, providing capital to advance its clinical programs [news · 2026-05-22].
What to weigh
- As of 2025-12-31, NervGen reported negative shareholders' equity of -$2.0M and a net loss of -$44.1M, indicating ongoing financial losses [sec].
- The company's cash position of $22.1M as of 2025-12-31 may require further financing to complete a Phase 3 trial, despite the recent $60M offering [sec].
- NervGen is a clinical-stage company with no approved products, and its lead candidate NVG-291 has not yet demonstrated efficacy in a pivotal trial [news · 2026-04-07].
From the filings
Quoted directly from source documents.
NervGen completed an End-of-Phase 2 meeting with the FDA and restored a Phase 3 registrational trial for NVG-291.
“NervGen Pharma Completes End-Of-Phase 2 Meeting With FDA, Restores Phase 3 Registrational Trial To Evaluate NVG-291 To Treat Chronic Tetraplegia”
News · April 7, 2026
NervGen announced a $60.0 million public offering of securities.
“NervGen Announces Pricing of US$60.0 Million Public Offering of Securities”
News · May 22, 2026
NervGen appointed Keith Vendola as CFO.
“NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer”
News · April 27, 2026
Catalyst timeline
- 2023-08-08 · Phase 2 Start: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Su - NCT: NCT05965700. Status: Completed. Endpoint: Electrophysiological. — This Phase 1b/2a study has been completed; results informed the Phase 3 design.
Risks & what to watch (3)›
Key risks
- Clinical and regulatory risk — NVG-291 has not yet completed a pivotal Phase 3 trial; failure to demonstrate efficacy or safety could halt development [news · 2026-04-07].
- Financial sustainability — Negative equity and recurring net losses raise going-concern risk; additional capital may be needed [sec].
- Dependence on single candidate — NervGen's pipeline is heavily reliant on NVG-291; any setback would significantly impact the company [news · 2026-04-07].
What to watch
- Initiation and enrollment of the Phase 3 registrational trial for NVG-291 in chronic tetraplegia [news · 2026-04-07].
- Cash runway and potential need for further financing following the $60M offering [news · 2026-05-22].
- Clinical data updates from the CONNECT SCI study and any new efficacy or safety readouts [news · 2026-02-11].
- Leadership execution under new CEO Dr. Adam Rogers and CFO Keith Vendola [sec · filed 2026-02-10][news · 2026-04-27].
Sources: Catalysts · News · SEC filings · Generated August 13, 2026 · How we verify sources →
Run NERVGEN PHARMA CORP. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NERVGEN PHARMA CORP. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.4 months
D/E 5.68
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
41
Total value held
$5.6M
| Holder | Shares | Value |
|---|---|---|
| pfg investments, llc | 201,000 | $758K |
| bank of america corp /de/ | 200,656 | $756K |
| marshall wace, llp | 200,359 | $755K |
| royal bank of canada | 171,961 | $648K |
| valley forge investment consultants inc adv | 77,698 | $293K |
| bank of montreal /can/ | 62,900 | $237K |
| captrust financial advisors | 62,367 | $235K |
| osaic holdings, inc. | 39,991 | $151K |
| patriot financial group insurance agency, llc | 37,000 | $139K |
| commonwealth equity services, llc | 33,350 | $126K |
Showing top 10 of 41 institutional holders of NERVGEN PHARMA CORP.. Open the full 13F history after sign-in.
Frequently asked questions
What is the AI investment thesis for NERVGEN PHARMA CORP.?
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic conditions, with a lead program (NVG-291) that has completed a Phase 1b/2a study and is preparing for a Phase 3 registrational trial.
Who is the CEO of NERVGEN PHARMA CORP.?
Dr. Adam H. Rogers M.D. is the chief executive officer of NERVGEN PHARMA CORP. (NGEN).
Where is NERVGEN PHARMA CORP. headquartered?
NERVGEN PHARMA CORP. (NGEN) is headquartered in Vancouver, BC, Canada.
What therapeutic areas does NERVGEN PHARMA CORP. focus on?
NERVGEN PHARMA CORP. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.